
 SENDERRA Specialty Pharmacy 1301 E. Arapaho Rd., Ste. 101 Richardson, TX 75081 <i>This prescription form is to be sent and received via fax</i>	Dermatology Enrollment Form Humira	Prescribing Practitioner: _____ NPI: _____	Supervising Physician: _____ NPI: _____
	Physician Offices Call: 855-460-7928	Address: _____ Telephone: _____ Fax: _____	Tax ID: _____
	Fax: 888-777-5645	Contact: _____	
	PATIENT INFORMATION		

Name: _____	<input type="checkbox"/> M <input type="checkbox"/> F	DOB: ____/____/____	SS#: _____
Street: _____	City: _____	State: _____	ZIP: _____
Tel: _____	Alt. Tel: _____	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION			
<input type="checkbox"/> New <input type="checkbox"/> Refill		Ship by: ____/____/____	SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____
Drug	Directions & Quantity	Refills	
Humira® Citrate Free <input type="checkbox"/> Psoriasis Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Adolescent HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 3) <input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) (Pre-filled Syringe only) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)		
	ADULT: <input type="checkbox"/> INITIAL: Inject 160 mg SQ on day 1, 80 mg on day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4)		
	ADOLESCENT: ***WEIGHT REQUIRED*** <input type="checkbox"/> INITIAL: Inject 160 mg SQ on day 1, 80 mg on day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4) ***Intended for weight ≥ 60 kg/132 lbs*** <input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2) ***Intended for weight 30 kg/66 lbs to <60 kg/132 lbs***		
Humira® <input type="checkbox"/> Psoriasis Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Adolescent HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)		
	ADULT: <input type="checkbox"/> INITIAL: Inject 160 mg SQ on day 1, 80 mg on day 15, then 40 mg once a week starting day 29 (Quantity: 6) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4)		
	ADOLESCENT: ***WEIGHT REQUIRED*** <input type="checkbox"/> INITIAL: Inject 160 mg SQ on day 1, 80 mg on day 15, then 40 mg once a week starting day 29 (Quantity: 6) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4) ***Intended for weight ≥ 60 kg/132 lbs*** <input type="checkbox"/> INITIAL: Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every other week (Quantity: 4) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2) ***Intended for weight 30 kg/66 lbs to <60 kg/132 lbs***		

MEDICAL INFORMATION			
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY			
PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
<input type="checkbox"/> Methotrexate <input type="checkbox"/> Soriatane <input type="checkbox"/> Clobetasol <input type="checkbox"/> Hydrocortisone <input type="checkbox"/> Calcipotriene <input type="checkbox"/> Stelara <input type="checkbox"/> Enbrel <input type="checkbox"/> _____ <input type="checkbox"/> _____	<input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____ <input type="checkbox"/> (_____) _____	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	_____ _____ _____ _____ _____ _____ _____ _____
PHOTOTHERAPY <input type="checkbox"/> UVA /UVB <input type="checkbox"/> Patient cannot afford	Tried & Failed (Duration): <input type="checkbox"/> (_____) _____ <input type="checkbox"/> Photosensitivity	Not Tolerated: <input type="checkbox"/> Risk of Skin Cancer	Contraindication: _____ _____ _____ _____ _____ _____ _____
<input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> L73.2 Hidradenitis suppurativa	<input type="checkbox"/> L40. _____ <input type="checkbox"/> Other: _____		_____ _____ _____ _____ _____ _____ _____
Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____	Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____		
Allergies: _____			
Additional Clinical Information: _____			



Affected Areas

Face Feet Groin Hands
 Nails Scalp Other: _____

Scoring tool used

BSA ISGA _____ % or Score: _____

American Academy of Dermatology Consensus Statement on Psoriasis Therapies	
<input type="checkbox"/> Psoriasis is covering greater than 10% of body surface area	<input type="checkbox"/> Psoriasis is on palms, soles, head and neck, or genitalia
<input type="checkbox"/> Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships.	<input type="checkbox"/> Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
INJECTION TRAINING	
<input type="checkbox"/> Patient has received pen and injection training	<input type="checkbox"/> Physician's office to provide injection training
<input type="checkbox"/> Senderra to coordinate injection training	
PRESCRIBING PRACTITIONER SIGNATURE	
To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescribing Practitioner: _____	Date: ____/____/____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.